This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Beijing Cotimes Biotech Ltd.. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011
Title: Xianzhao Jia: Innovator in TRAIL Receptor-Binding Agents
Introduction
Xianzhao Jia is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of TRAIL receptor-binding agents. His work focuses on innovative solutions for cancer therapy, showcasing his commitment to advancing medical science.
Latest Patents
Xianzhao Jia holds a patent for TRAIL receptor-binding agents and their uses. This invention pertains to the preparation of anti-TRAIL receptor antibodies that recognize a common antigen determinant shared by TRAIL-R1 and TRAIL-R2 receptors. The TRAIL receptor-binding agents are designed to induce apoptosis in human cancer cells, making them valuable tools in cancer therapy.
Career Highlights
Xianzhao Jia is associated with Beijing Cotimes Biotech Ltd., where he applies his expertise in biotechnology to develop groundbreaking therapies. His innovative approach has positioned him as a key figure in the field, contributing to advancements that may significantly impact cancer treatment.
Collaborations
Xianzhao has collaborated with notable colleagues, including Zheng Yu and Min Zhou. These partnerships enhance the research and development efforts at Beijing Cotimes Biotech Ltd., fostering an environment of innovation and discovery.
Conclusion
Xianzhao Jia's work in developing TRAIL receptor-binding agents exemplifies his dedication to improving cancer therapies. His contributions to biotechnology are paving the way for new treatment options that could benefit countless patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile